All Pharma News
Century, Elevation to cut assets, staff; Nabriva winds down

Century, Elevation to cut assets, staff; Nabriva winds down
James Waldron FIERCE BIOTECH
06 Jan 2023
Share Share
Nabriva Therapeutics Provides Corporate Update

Nabriva Therapeutics Provides Corporate Update
GLOBENEWSWIRE
06 Jan 2023
Share Share
Nabriva Announces Positive Results from Phase 1 Trial of XENLETA® (lefamulin)

Nabriva Announces Positive Results from Phase 1 Trial of XENLETA® (lefamulin)
GLOBENEWSWIRE
28 Nov 2022
Share Share
Nabriva halts R&D, lays off 40% of staff in commercial refocus

Nabriva halts R&D, lays off 40% of staff in commercial refocus
James Waldron FIERCEBIOTECH
11 Nov 2022
Share Share
Nabriva Therapeutics Pivoting Strategic Focus Reports 3Q Financial Results

Nabriva Therapeutics Pivoting Strategic Focus Reports 3Q Financial Results
GLOBENEWSWIRE
10 Nov 2022
Share Share
Nabriva Therapeutics to Report 3Q 2022 Financial Results and Recent Corporate

Nabriva Therapeutics to Report 3Q 2022 Financial Results and Recent Corporate
GLOBENEWSWIRE
07 Nov 2022
Share Share
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
GLOBENEWSWIRE
15 Sep 2022
Share Share
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th AnnualGIC

Nabriva Therapeutics to Participate in the H.C. Wainwright 24th AnnualGIC
GLOBENEWSWIRE
06 Sep 2022
Share Share
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA®

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA®
GLOBENEWSWIRE
11 Aug 2022
Share Share
Nabriva Therapeutics Reports Second Quarter 2022 Financial Results

Nabriva Therapeutics Reports Second Quarter 2022 Financial Results
GLOBENEWSWIRE
03 Aug 2022
Share Share